Revolution Medicines, Inc. Common Stock
RVMD
$177.96
-5.97%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel small-molecule therapies that bind directly to RAS variants — its RAS(ON) inhibitor platform — targeting RAS-addicted cancers such as pancreatic, colorectal, and lung tumors, within the highly competitive biotechnology sector. The company has transitioned from a pure discovery-stage story into a late-clinical/early-commercial contender, differentiated by structure-based drug discovery capabilities aimed at unconventional binding sites that have historically been considered undruggable. The investor narrative is now dominated by the rapid regulatory progress of its lead asset daraxonrasib (Rasonque), which reportedly won FDA approval roughly one month after filing, alongside Phase 3 pancreatic cancer data showing survival roughly double that of chemotherapy, and analysts modeling peak sales near $11.5 billion. That optimism is tempered by a debate over valuation after the stock's multi-fold surge, a $2.2 billion upsized equity raise that diluted shareholders but fortified the balance sheet, and the inherent binary risk of a pre-revenue biotech scaling toward commercialization.…
RVMD
Revolution Medicines, Inc. Common Stock
$177.96
Related headlines
RVMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $257.80 and implied upside of +44.9% versus the current price.
Average Target
$257.80
0 analysts
Implied Upside
+44.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $320
Analyst target range
Coverage is broad and overwhelmingly bullish: 24 analysts cover RVMD with a consensus recommendation of "strong_buy" (mean rating of 1.28 on a 1-to-5 scale where 1 is a strong buy), and the average target price of $257.80 implies roughly +44.9% upside from the current $177.96. The consensus leans decisively bullish, reinforced by a wave of reiterated Buy/Outperform ratings from B of A Securities, Stifel, Needham, Guggenheim, UBS, Evercore ISI, Wedbush, Oppenheimer, RBC Capital, and Truist between late August and late September 2026 — notably, all ten recent actions were reiterations of existing positive ratings rather than downgrades, suggesting analysts are holding conviction through the recent pullback. The target range is wide, from a low of $179.00 (essentially at the current price, implying ~0.6% upside) to a high of $320.00 (roughly +79.8% upside), a spread of about 79% of the current price that signals meaningful disagreement about the magnitude of the commercial opportunity. The high target likely assumes rapid daraxonrasib uptake, label expansion across RAS-driven tumor types, and multiple expansion consistent with the ~$11.5 billion peak-sales thesis, while the low target appears to price in a more conservative launch, competitive pressure, or simply the stock having already captured much of the near-term upside after its 5x-plus run. The wide dispersion, combined with the stock trading below the average target but well above the low end, suggests high uncertainty typical of a binary, event-driven biotech — investors should treat the consensus as directionally positive but recognize that the low target reflects real risk of disappointment.
Bulls vs Bears: RVMD Investment Factors
The bull case currently holds stronger evidence: a validated, fast-approved drug with survival roughly double chemotherapy, a $2.2 billion cash cushion, and a 24-analyst strong_buy consensus with +44.9% implied upside. The bear case rests less on fundamentals than on price — a 9.28x P/B multiple, a 258% one-year gain, and a -$1.59 billion TTM cash burn leave no room for error. The single most important tension is whether daraxonrasib's commercial ramp can track toward the ~$11.5 billion peak-sales thesis fast enough to justify the valuation; if launch metrics confirm that trajectory, the recent 9% pullback is a buying opportunity, but if uptake lags, the stock has significant air beneath it. Near-term technicals have rolled over (down 9.17% in a month, -5.97% in the latest session), suggesting the market is already beginning to test that question.
Bullish
- Daraxonrasib survival data redefines standard of care: Phase 3 pancreatic cancer data showed survival roughly double that of chemotherapy, a magnitude of benefit rarely seen in this indication. With FDA approval reportedly granted about one month after filing, the regulatory de-risking is substantial and the commercial launch is already underway.
- Analyst consensus strongly bullish with 45% upside: 24 analysts carry a mean rating of 1.28 (strong_buy) with an average target of $257.80, implying +44.9% upside from $177.96. All ten recent rating actions between late August and late September 2026 were reiterations of Buy/Outperform, showing conviction held through the pullback.
- Fortified balance sheet removes near-term financing risk: The $2.2 billion April 2026 raise lifted cash to $820.29 million with a current ratio of 7.14 and debt-to-equity of just 0.097. This funds the commercial build-out without immediate dilution risk, a rare luxury for a launch-stage biotech.
- Massive revenue scale-up expected by consensus: Consensus projects average revenue of approximately $7.77 billion (range $3.80B to $13.94B) and average EPS of $14.47 as the franchise scales. Against a $15.1 billion market cap, that implies a forward multiple that is far from demanding if even the low end materializes.
Bearish
- Valuation prices in near-perfect execution: Price-to-book of 9.28x sits near the upper end of its own historical band (up from ~3.2x at Q4 2025 and a peak of 15.15x in Q2 2026), with no revenue and deeply negative earnings. The market is capitalizing pipeline optionality, leaving little margin for clinical, regulatory, or competitive disappointment.
- Cash burn is accelerating sharply: Q2 2026 net loss widened to -$644.37 million from -$247.79 million a year earlier, with R&D up from $224.13M to $394.92M and SG&A up from $40.58M to $110.21M. TTM free cash flow is -$1.59 billion, meaning another capital raise is likely if commercialization underperforms.
- Momentum has rolled over near-term: The stock is down 9.17% over one month and 4.40% over three months, with relative strength of -10.39% versus SPY over one month. The -5.97% single-day drop on 2.97 million shares from $189.26 to $177.96 signals profit-taking after a parabolic run.
- Wide analyst target dispersion signals uncertainty: Targets range from $179.00 (essentially flat to current price) to $320.00, a spread of roughly 79% of the current price. The low target reflects real risk that the stock has already captured most near-term upside after its 5x-plus run.
RVMD Technical Analysis
RVMD is in a powerful, sustained uptrend: the stock is up 258.21% over the trailing year and 125.21% year-to-date, massively outperforming the S&P 500's 15.53% and 11.93% respective gains (relative strength of +242.68% over one year). At the current price of $177.96, the stock sits roughly 79% of the way through its 52-week range of $52.40 to $224.31 — closer to the highs than the lows, but notably about 20.7% below the 52-week high, indicating the momentum leadership remains intact while the stock digests a sharp multi-month advance rather than pressing to new highs. This positioning is characteristic of a high-momentum biotech in a consolidation phase after a parabolic run, where the trend is still up but the easy money has been made. Recent momentum has clearly decelerated and turned negative: the stock is down 9.17% over the past month and 4.40% over three months, a stark divergence from the +258% one-year gain, with relative strength of -10.39% versus SPY over one month and -7.09% over three months. The most recent session was especially weak, with a -5.97% single-day drop from a previous close of $189.26 to $177.96 on volume of roughly 2.97 million shares, and the 180-day series shows a rolling-over pattern from the August peak near $221.15 toward the mid-$170s. This one-month/one-year divergence signals mean reversion and profit-taking after an extended run rather than a confirmed trend reversal, but the velocity of the recent decline warrants caution. Key technical levels are defined by the 52-week range: support sits near the $52.40 low (far below current levels and unlikely to be tested absent a catastrophic clinical or commercial setback), with nearer-term support implied around the recent $177–$188 congestion zone, while resistance is the $224.31 52-week high. A breakout above $224.31 would confirm resumption of the primary uptrend and likely invite momentum buyers, whereas a decisive breakdown below the $177 area could open a deeper retracement toward the $150s. With a beta of 1.401, RVMD is roughly 40% more volatile than the market, and a maximum drawdown of -24.95% underscores that position sizing and stop discipline are essential for this name.
Beta
1.40
1.40x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$52-$224
Price range past year
Annual Return
+258.2%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | -9.2% | +0.2% |
| 3m | -4.4% | +2.9% |
| 6m | +19.7% | +8.4% |
| 1y | +258.2% | +14.9% |
| ytd | +125.2% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is effectively pre-revenue: reported revenue is $0 in the most recent quarter (Q2 2026) and in each of the prior four quarters, with the only revenue line in the segment data being $7.014 million of collaboration revenue in an earlier period. Consequently, there is no meaningful revenue growth trajectory to analyze — the investment case rests entirely on pipeline milestones and the commercial ramp of daraxonrasib following its reported FDA approval, with consensus estimates projecting average revenue of approximately $7.77 billion (range $3.80 billion to $13.94 billion) as the franchise scales. The absence of product revenue means traditional growth metrics are not yet informative; investors should instead track prescription trends, launch metrics, and label expansion as the true fundamental drivers. Profitability is deeply negative, as expected for a company investing heavily ahead of commercialization: Q2 2026 net income was -$644.37 million (EPS of -$3.06), EBITDA was -$620.59 million, and gross margin is 0% given the lack of product sales. The loss trajectory is widening, not narrowing — net loss expanded from -$247.79 million in Q2 2025 to -$644.37 million in Q2 2026, and R&D spending rose from $224.13 million to $394.92 million over the same period, alongside SG&A growth from $40.58 million to $110.21 million as the company builds commercial infrastructure. This is consistent with a biotech transitioning from clinical-stage to launch-stage, where margin compression is a deliberate investment rather than deterioration, but it means profitability remains years away and highly dependent on revenue ramp. The balance sheet is the company's key strength: the $2.2 billion April 2026 equity raise lifted cash and equivalents to $820.29 million at Q2 2026, the current ratio stands at a robust 7.14, and debt-to-equity is a very low 0.097, while ROE of -69.35% and ROA of -30.12% reflect the cash burn against a growing equity base. Free cash flow is deeply negative at -$1.59 billion TTM (Q2 2026 free cash flow of -$745.31 million), driven by operating cash flow of -$741.48 million and modest capex of -$3.82 million, meaning the company is funding its launch entirely from its raised capital rather than internal cash generation. The low leverage and large cash cushion reduce near-term financing risk, but the burn rate implies another raise could be needed if commercialization underperforms.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Because net income is negative (-$644.37 million in Q2 2026) and EBITDA is also negative (-$620.59 million), neither the PE nor EV/EBITDA ratio is meaningful; the trailing PE of -13.39x and EV/EBITDA of -13.68x are artifacts of losses, and the PS ratio is reported as 0 given the absence of revenue. The most informative metric is therefore the forward PE of -30.55x paired with the price-to-book ratio of 9.28x and price-to-sales of 0, which together signal that the market is valuing RVMD on pipeline optionality and expected future revenue rather than current earnings. The gap between the negative trailing and forward earnings multiples reflects consensus expectations that losses will persist near-term even as revenue begins to materialize, with estimated EPS averaging $14.47 (range $4.87 to $29.45) once the franchise scales. Peer comparison is constrained by the absence of a clean industry-average multiple in the provided valuation data, but contextually a 9.28x price-to-book for a pre-revenue biotech is a premium multiple that prices in substantial commercial success; the negative PEG of -0.20 and negative price-to-cash-flow of -16.87x are not decision-useful given the loss-making profile. The premium is arguably justified only if daraxonrasib achieves the ~$11.5 billion peak-sales estimate cited by analysts, which would make current multiples look reasonable on a forward basis — but it leaves little margin for clinical, regulatory, or competitive disappointment. Historically, RVMD's price-to-book has expanded dramatically, from roughly 3.2x at the end of 2025 (Q4 2025) to 9.28x currently and as high as 15.15x at Q2 2026, while its PE has ranged from about -6.3x to -15.3x over the past several years. The current 9.28x P/B sits near the upper end of its own historical band, indicating the market is pricing in optimistic expectations and that valuation support from book value is thin relative to the stock's recent history.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's pre-revenue status and accelerating burn. Revenue was $0 in Q2 2026 and each of the prior four quarters, while the quarterly net loss widened to -$644.37 million from -$247.79 million a year earlier and TTM free cash flow stands at -$1.59 billion. R&D spending rose to $394.92 million and SG&A to $110.21 million as the company builds commercial infrastructure, meaning profitability is years away and entirely dependent on the daraxonrasib launch. The $820.29 million cash balance, 7.14 current ratio, and 0.097 debt-to-equity provide a buffer, but at the current burn rate another equity raise — and further dilution — is a realistic possibility if commercialization underperforms.
Market and competitive risks are dominated by valuation compression. At 9.28x price-to-book — near the top of its historical range and up from ~3.2x at Q4 2025 — the stock discounts substantial commercial success, and the negative forward PE of -30.55x and PEG of -0.20 offer no earnings-based support. With a beta of 1.401, RVMD is roughly 40% more volatile than the market, so any rotation away from high-multiple biotech or a rise in discount rates would hit it disproportionately. Recent commentary has begun flagging this: Motley Fool noted the 5x surge "may already price in much of the upside" and that the risks make the stock "unsuitable for most investors at current levels," while competitive threats in RAS-addicted cancers from larger oncology players remain a structural overhang.
Worst-case scenario: launch prescription trends disappoint in the first two reported quarters, a competitor posts superior RAS(ON) data, and the market re-rates the stock toward the low analyst target of $179.00 — essentially flat — before breaking lower toward the $150s congestion zone implied by technical support. A more severe outcome, such as a label setback or safety signal, could retrace toward the $52.40 52-week low, though that would require a catastrophic event. From the current $177.96, a realistic adverse scenario is a decline to the $150s (roughly -15% to -20%), with the stock's -24.95% max drawdown as a guide to how far sentiment-driven selling can run; a full retrace to the 52-week low would represent a loss of approximately -70%.